9Unicorns, Venture catalysts and various angel investors participated in the round. Funds will used for improving the solution to deliver better patient outcomes at scale and creating better awareness and reach. Fitterfly is a scientifically validated DTx solution patient outcomes published in international Endocrinology forums.
Fitterfly, a health-tech company working in the field of Digital Therapeutics (DTx) has raised $3.1M (INR 22.3Cr) in a Pre-Series A round led by Fireside Ventures, which also saw participation from 9Unicorns – the accelerator fund of Venture Catalysts, Venture Catalysts and angel investors from India, USA and Singapore. Funds will be primarily used for improving the solution to deliver better patient outcomes at scale and impacting a large number of people by creating better awareness and reach.
Kanwaljit Singh, Managing Partner at Fireside Ventures also joins as a board member. Fireside is known for investing in start-ups like boAt, Mamaearth, Vahdam, Yogabar etc. and helping them become strong consumer brands people love.
Fitterfly offers scientifically validated and personalized digital therapeutics (DTx) programs for Diabetes, Pregnancy, and PCOS & Obesity to deliver health outcomes that truly matter. The 140+ member strong team comprises senior doctors, nutritionists, psychologists, fitness experts, management experts, and technologists working together with the sole aim of creating a healthy tomorrow for society at large. Designed to work complementary to the Doctor’s medical therapy, Fitterfly DTx programs offer 360° guidance around nutrition, exercise, sleep, stress and other factors which affect health outcomes. More than 10,000 people have subscribed and benefited from Fitterfly’s programs.
Fitterfly’s Diabetes DTx program, Diabefly available on the Fitterfly Wellness App, is a highly scientific program that uses cutting-edge data tools to correlate data from continuous glucose monitoring devices and find the real reasons for point-to-point fluctuations in blood sugar – termed Personalised Glycemic Response – customised for each patient. In addition, using insights from one of India’s most comprehensive nutrition database developed in-house, Diabefly has achieved better blood sugar control in 85% of clients and medicine reduction in 30% of patients. These clinically validated outcomes have been presented at the American Association of Clinical Endocrinologists, ENDO 2021 and a host of other conferences internationally.
On investing in the health-tech platform, Kanwaljit Singh, Managing Partner, Fireside Ventures said, “In the current post-pandemic era, we, at Fireside, believe that brands, platforms, and enterprises that address and serve well-being, holistic living, and health needs and concerns of consumers have acquired greater acceptance. Consumers are now amenable and willing to consider and adopt digital solutions that promise to improve and enhance their quality of life and keep them in a state of good health. The segment of digital therapeutics represents an incredible growth opportunity for us. As a consumer-focused fund, we want to play a more proactive and dynamic role in building and shaping consumer behaviour and the lifestyle choices they make. In line with this objective, we are confident and excited about our investment in Fitterfly.”
Speaking on the fundraise Dr. Arbinder Singal, Co-Founder & CEO, Fitterfly said “We are excited to have Fireside and Kanwaljit Singh join us on this journey and build a lasting outcome-focused company. Fireside team’s consumer focus and branding experience will help us build a great brand in the healthcare space. We plan to expand our DTx portfolio and invest in developing AI and smart health tracking tools. The timely and relevant real-world data generated will enable beneficial interactions between patients, caregivers, and support networks to permit personalized and human-centric treatments with greater transparency and improved outcomes.”
Anuj Golecha, Co-Founder, 9Unicorns said, “Healthcare and digital technology are the two primary themes of the post-2020 era. The digital has become ingrained in the DNA of the post-pandemic world, transforming the mode of operations of almost every global sector. Healthcare, wellness, and therapeutic industries are no exception. Fitterfly is one such new-age brand rising to the occasion to fuse the two big themes of the post-pandemic era. At 9Unicorns, we are always on a look out for ventures leveraging tech-based innovations to solve the most pressing pain points in society. With its focus on enabling digital therapeutics (DTx) and healthcare for patients with chronic diseases, Fitterfly crossed all the boxes on our checklist. We wish them continued success.”
In June 2019, Fitterfly had raised a seed round of 1 Mn USD from HNIs, family & friends.
Fitterfly is a smart, personal digital therapeutic solution that is an anytime, anywhere companion for patients to achieve their health goals. The company offers a clinically validated, digital-led therapy that connects patients, health coaches and healthcare providers in meaningful ways to enable sustainable behaviour change that is at the core of good health. Fitterfly achieves transformational outcomes for patients with personalised, data and coaching-led behaviour change via Vogital (voice and digital) touch points with a user-centric app. The programs are based on glocally accepted, evidence-based protocols and cutting-edge research.
Fitterfly’s current product suite includes scientific and hyper-personalized DTx programs for diabetes, PCOS, obesity, pregnancy, and child wellness. They are the preferred digital therapeutic partner for a large number of doctors, hospitals, organisations like pharma companies, corporates and medical device companies.
The company was Co-Founded by Dr. Arbinder Singal- CEO, Shailesh Gupta- COO, and Jayesh Sawant- CTO/CPO.